Antipyrine Arnica Montana Barium Carbonate Bismuth

證據等級: L5 預測適應症: 0

目錄

  1. Antipyrine Arnica Montana Barium Carbonate Bismuth
  2. Multi-Ingredient Homeopathic Formula: No Drug Repurposing Predictions Generated
    1. One-Sentence Summary
    2. Quick Overview
    3. Clinical Trial Evidence
    4. Literature Evidence
    5. Safety Considerations
    6. Conclusion and Next Steps
    7. Disclaimer

## 藥師評估報告

Multi-Ingredient Homeopathic Formula: No Drug Repurposing Predictions Generated

Ingredients: Antipyrine · Arnica Montana · Barium Carbonate · Bismuth Subnitrate · Calcium Fluoride · Delphinium Staphisagria Seed · Hypericum Perforatum · Iron · Matricaria Chamomilla · Plantago Major · Sepia Officinalis Juice · Spigelia Anthelmia · Strychnos Nux-Vomica Seed · Veratrum Album Root


One-Sentence Summary

This product is a complex mixture of 14 components spanning a synthetic analgesic (antipyrine), homeopathic botanicals, and mineral preparations, with no formal market registration found in the evaluated jurisdiction. The TxGNN model did not generate any repurposing predictions for this compound, most likely because no recognized DrugBank identifier could be resolved for the multi-ingredient entry as a whole. Without a prediction target and with all regulatory and safety fields absent, no evidence-level evaluation can be conducted at this time.


Quick Overview

Item Content
Original Indication No licensed indications on record
Predicted New Indication No predictions generated
TxGNN Prediction Score N/A
Evidence Level Below L5 — TxGNN produced no output for this entry
US Market Status Not Marketed
Number of NDAs 0
Recommended Decision Hold

Clinical Trial Evidence

Currently no related clinical trials registered.


Literature Evidence

Currently no related literature available.


Safety Considerations

Please refer to the package insert for safety information.


Conclusion and Next Steps

Decision: Hold

Rationale: No DrugBank ID could be resolved for this multi-ingredient homeopathic preparation, preventing TxGNN from generating any repurposing candidates; combined with zero market registrations and absent safety data, there is no actionable basis to proceed.

To proceed, the following is needed:

  • Ingredient decomposition: Identify which component(s) should serve as the primary active ingredient and resolve a corresponding DrugBank ID (e.g., Antipyrine → DB04946; Hypericum Perforatum → DB01070)
  • Mechanism of action (MOA): Retrieve pharmacological mechanism for the lead component via DrugBank API — currently a High-severity data gap (DG002)
  • Original indication: Clarify the approved therapeutic use in at least one reference jurisdiction
  • Safety data: Download and parse the product package insert to fill the Blocking-severity gap on warnings and contraindications (DG001)
  • Re-run TxGNN: Once a single INN or DrugBank ID is confirmed, resubmit as a single-ingredient query to obtain a valid prediction score and ranked indication list

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Copyright © 2026 UsTxGNN Project. For research purposes only.

This site uses Just the Docs, a documentation theme for Jekyll.